Indian Corporates Gear Up for Q1 FY26 Results: ACC, PNB Housing, and Mankind Pharma Set Board Meeting Dates

Mumbai, July 15: Several prominent Indian companies have announced their upcoming board meetings to consider and approve unaudited financial results for the first quarter of the financial year 2025-26 (Q1 FY26), which concluded on June 30, 2025. These announcements are critical for market participants, providing insights into corporate performance. Notably, one of these companies will also be considering the declaration of an interim dividend.

In accordance with the Securities and Exchange Board of India (SEBI) (Prohibition of Insider Trading) Regulations, 2015, a ‘trading window closure’ period is enforced before the release of financial results. This measure aims to prevent “designated persons” (such as directors, key managerial personnel, and certain employees) and their “immediate relatives” from trading in the company’s securities when they might possess Unpublished Price Sensitive Information (UPSI).

This is crucial for maintaining market fairness and preventing insider trading. SEBI has continuously strengthened this framework, including automating PAN freezing for designated persons and their immediate relatives, particularly for companies in benchmark indices, with the latest phase of this rule being effective from July 1, 2025, for the top 500 listed companies.

Here’s a detailed look at the upcoming board meetings and their implications:

ACC Limited (NSE: ACC)

ACC Limited, a significant player in the Indian cement industry and part of the Adani Group, has announced that its Board of Directors will convene on Thursday, July 24, 2025. The primary agenda for this meeting is to review and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26).

• Company Profile: ACC Limited is a leading manufacturer of cement and ready-mix concrete in India, known for its extensive network of plants and distribution channels across the country and its focus on sustainable building materials.
• Reporting Period: Q1 FY26 (April–June 2025)
• Audit Status: Unaudited
• Trading Window Closure: In adherence to SEBI regulations, the trading window for ACC shares commenced its closure on July 1, 2025, and will remain shut until July 26, 2025. This period extends for 48 hours after the declaration of financial results to ensure that all UPSI is made public before trading resumes for insiders.

PNB Housing Finance Limited (NSE: PNBHOUSING)

PNB Housing Finance Limited, a publicly listed housing finance company promoted by Punjab National Bank, will hold its Board of Directors meeting on Monday, July 21, 2025. The board’s key agenda will be to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2025 (Q1 FY26).

• Company Profile: PNB Housing Finance Limited operates under the regulation of the National Housing Bank (NHB) and offers a broad spectrum of housing and non-housing loans, including home loans, loans against property, and construction finance. It is listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
• Reporting Period: Q1 FY26 (April–June 2025)
• Audit Status: Unaudited
• Trading Window Closure: The company has confirmed that its trading window was closed from July 1, 2025, and will remain shut until further notice, aligning with SEBI guidelines to prevent insider trading ahead of financial disclosures.

Mankind Pharma Limited (NSE: MANKIND)

Mankind Pharma Limited, a prominent pharmaceutical company known for its diverse range of formulations, has announced that its Board of Directors will meet on Thursday, July 31, 2025. The board will not only review and approve the unaudited standalone and consolidated financial results for Q1 FY26 but will also consider the declaration of an interim dividend for its shareholders.

• Company Profile: Mankind Pharma Limited is a publicly listed pharmaceutical company engaged in developing, manufacturing, and marketing various pharmaceutical formulations. It operates in both domestic and international markets, with a strategic focus on providing affordable healthcare solutions.
• Reporting Period: Q1 FY26 (Quarter ended June 2025)
• Audit Status: Unaudited
• Dividend Consideration: Interim Dividend
• Trading Window Closure: As per the company’s compliance framework and SEBI’s Prohibition of Insider Trading Regulations, the trading window for Mankind Pharma was closed on July 1, 2025, and will remain shut until August 2, 2025. This closure period is critical to ensure fair dissemination of price-sensitive information, especially given the consideration of a dividend.

Summary of Key Dates and Details

What Does This Mean for the Investors?

For investors, the upcoming board meetings of ACC, PNB Housing Finance, and Mankind Pharma signal key decision points that could impact stock prices. Quarterly results will offer insight into sectoral performance trends-cement, housing finance, and pharma-and help gauge company-specific growth momentum. Mankind Pharma’s possible interim dividend adds a short-term incentive for shareholders. Meanwhile, trading window closures reinforce transparency and ensure a level playing field. Investors may want to monitor these stocks closely around result dates for potential trading or investment opportunities based on earnings surprises or dividend announcements.

Share Price Performance

As of 10:00 AM on July 15th, the shares of these companies were trading at:

• ACC Limited – ₹1,984.70 (up by 0.34% or ₹6.80)
• PNB Housing – ₹1,080 (down by 0.68% or ₹7.40)
• Mankind Pharma – ₹2,666 (down by 1.13% or ₹30.50)

REF:https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_59731_1482591_14072025084630_WEB.xml

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations